Follow
Elvin D. de Araujo
Elvin D. de Araujo
Verified email at utoronto.ca
Title
Cited by
Cited by
Year
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ...
Leukemia 32 (5), 1135-1146, 2018
1412018
Direct targeting options for STAT3 and STAT5 in cancer
A Orlova, C Wagner, ED de Araujo, D Bajusz, HA Neubauer, M Herling, ...
Cancers 11 (12), 1930, 2019
742019
Structural and functional consequences of the STAT5BN642H driver mutation
ED de Araujo, F Erdogan, HA Neubauer, D Meneksedag-Erol, ...
Nature communications 10 (1), 2517, 2019
712019
CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence
N Garg, D Bakhshinyan, C Venugopal, S Mahendram, DA Rosa, ...
Oncogene 36 (5), 606-617, 2017
642017
Structural implications of STAT3 and STAT5 SH2 domain mutations
ED de Araujo, A Orlova, HA Neubauer, D Bajusz, HS Seo, ...
Cancers 11 (11), 1757, 2019
542019
The ERBB-STAT3 axis drives Tasmanian devil facial tumor disease
L Kosack, B Wingelhofer, A Popa, A Orlova, B Agerer, B Vilagos, P Majek, ...
Cancer Cell 35 (1), 125-139. e9, 2019
452019
JAK‐STAT core cancer pathway: An integrative cancer interactome analysis
F Erdogan, TB Radu, A Orlova, AK Qadree, ED de Araujo, J Israelian, ...
Journal of cellular and molecular medicine 26 (7), 2049-2062, 2022
402022
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia
JM Gawel, AE Shouksmith, YS Raouf, N Nawar, K Toutah, S Bukhari, ...
European Journal of Medicinal Chemistry 201, 112411, 2020
362020
Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)‐Resistant CML Lines While Circumventing Pharmacokinetic Liabilities
AM Ali, RF Gómez‐Biagi, DA Rosa, PS Lai, WL Heaton, JS Park, ...
ChemMedChem 11 (8), 850-861, 2016
352016
Characterization of conformationally constrained benzanilide scaffolds for potent and selective HDAC8 targeting
MM Hassan, J Israelian, N Nawar, G Ganda, P Manaswiyoungkul, ...
Journal of Medicinal Chemistry 63 (15), 8634-8648, 2020
312020
Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer
AE Shouksmith, F Shah, ML Grimard, JM Gawel, YS Raouf, M Geletu, ...
Journal of medicinal chemistry 62 (5), 2651-2665, 2019
312019
Development of HDAC inhibitors exhibiting therapeutic potential in T-cell prolymphocytic leukemia
K Toutah, N Nawar, S Timonen, H Sorger, YS Raouf, S Bukhari, J von Jan, ...
Journal of medicinal chemistry 64 (12), 8486-8509, 2021
282021
Class I/IIb-selective HDAC inhibitor exhibits oral bioavailability and therapeutic efficacy in acute myeloid leukemia
AE Shouksmith, JM Gawel, N Nawar, D Sina, YS Raouf, S Bukhari, L He, ...
ACS Medicinal Chemistry Letters 11 (1), 56-64, 2019
242019
High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains
ED de Araujo, P Manaswiyoungkul, J Israelian, J Park, K Yuen, ...
Journal of pharmaceutical and biomedical analysis 143, 159-167, 2017
212017
The first nucleotide binding domain of the sulfonylurea receptor 2A contains regulatory elements and is folded and functions as an independent module
ED de Araujo, LK Ikeda, S Tzvetkova, V Kanelis
Biochemistry 50 (31), 6655-6666, 2011
202011
Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma
N Nawar, S Bukhari, AA Adile, Y Suk, P Manaswiyoungkul, K Toutah, ...
Journal of medicinal chemistry 65 (4), 3193-3217, 2022
182022
Sensitive detection of broad-Spectrum bacteria with small-molecule fluorescent excimer chemosensors
AD Cabral, N Rafiei, ED de Araujo, TB Radu, K Toutah, D Nino, ...
ACS sensors 5 (9), 2753-2762, 2020
182020
Physiological characterization and light response of the CO2-concentrating mechanism in the filamentous cyanobacterium Leptolyngbya sp. CPCC 696
ED de Araujo, J Patel, C de Araujo, SP Rogers, SM Short, DA Campbell, ...
Photosynthesis research 109, 85-101, 2011
182011
Phosphorylation-dependent changes in nucleotide binding, conformation, and dynamics of the first nucleotide binding domain (NBD1) of the sulfonylurea receptor 2B (SUR2B)
ED de Araujo, CP Alvarez, JP Lopez-Alonso, CR Sooklal, M Stagljar, ...
Journal of Biological Chemistry 290 (37), 22699-22714, 2015
172015
Unique molecular interaction with the histone deacetylase 6 catalytic tunnel: Crystallographic and biological characterization of a model chemotype
OO Olaoye, PR Watson, N Nawar, M Geletu, A Sedighi, S Bukhari, ...
Journal of medicinal chemistry 64 (5), 2691-2704, 2021
162021
The system can't perform the operation now. Try again later.
Articles 1–20